Stock IMM IMMUTEP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Immutep Limited Stock

Equities

IMM

AU000000IMM6

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:45 2024-04-19 am EDT 		5-day change 1st Jan Change
0.355 AUD +1.43% Intraday chart for Immutep Limited -5.33% +2.90%
Apr. 18 Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761 CI
Apr. 18 Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial MT

Financials

Sales 2024 * 3.19M 2.05M Sales 2025 * 16.98M 10.89M Capitalization 422M 271M
Net income 2024 * -45M -28.87M Net income 2025 * -43M -27.59M EV / Sales 2024 * 108 x
Net cash position 2024 * 76.33M 48.98M Net cash position 2025 * 47.15M 30.25M EV / Sales 2025 * 22.1 x
P/E ratio 2024 *
-8.95 x
P/E ratio 2025 *
-9.75 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.19%
More Fundamentals * Assessed data

Chart Immutep Limited

Dynamic Chart

Latest news about Immutep Limited

Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761 CI
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial MT
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer CI
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay MT
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial MT
Encouraging results for Immutep's cancer therapies FI
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti CI
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss MT
Immutep Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer CI
Immutep Doses First Patient in Cancer Trial MT
Immutep Limited Announces Change of Registered Office Address CI
Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer CI
Immutep Receives $1.7 Million Research, Development Tax Incentive From French Government MT
Immutep Secures 1.6 Million Euro French R&D Tax Rebate for 2022 MT
More news

Analyst Recommendations on Immutep Limited

Baird Initiates Immutep With Outperform Rating, $7 Price Target MT
Maxim Group Adjusts Price Target on Immutep to $10 From $8, Keeps Buy Rating MT
Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers CI
AIPAC final data as expected: Phase III supported with maintaining a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey) PU
O/W: IMMune to failure - Initiating coverage with a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey) PU
More recommendations

Press releases Immutep Limited

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 AQ
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey) PU
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76 PU
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer AQ
Immutep : Corporate Presentation PU
More press releases

News in other languages on Immutep Limited

Pfizer : une étude clinique de phase I conduite avec Immutep
More news

Quotes and Performance

1 day+1.43%
1 week-5.33%
Current month-6.58%
1 month-5.33%
3 months-1.39%
6 months+29.09%
Current year+2.90%
More quotes

Highs and lows

1 week
0.34
Extreme 0.342
0.38
1 month
0.34
Extreme 0.342
0.42
Current year
0.33
Extreme 0.325
0.42
1 year
0.23
Extreme 0.225
0.42
3 years
0.23
Extreme 0.225
0.73
5 years
0.10
Extreme 0.1
0.73
10 years
0.10
Extreme 0.1
1.90
More quotes

Managers and Directors - Immutep Limited

Managers TitleAgeSince
Marc Voigt CEO
 Chief Executive Officer 51 10-12-31
David Fang DFI
 Director of Finance/CFO - 18-02-28
Florian Vogl CTO
 Chief Tech/Sci/R&D Officer - 23-04-30
Members of the board TitleAgeSince
Russell Howard CHM
 Chairman 74 13-05-07
Marc Voigt CEO
 Chief Executive Officer 51 10-12-31
Anne Anderson BRD
 Director/Board Member - Feb. 13
More insiders

Quotes

Date Price Change Volume
24-04-19 0.355 +1.43% 1,296,088
24-04-18 0.35 0.00% 540,120
24-04-17 0.35 -2.78% 589,956
24-04-16 0.36 0.00% 1,131,336
24-04-15 0.36 -4.00% 963,039

Delayed Quote Australian S.E., April 19, 2024 at 02:10 am EDT

More quotes

Company Profile

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Sector
Biotechnology & Medical Research
Calendar
2024-05-14 - European Society for Medical Oncology Meeting
More about the company

Income Statement Evolution

More financial data

Ratings for Immutep Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.355 AUD
Average target price
0.9 AUD
Spread / Average Target
+153.52%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IMMUTEP LIMITED Stock Immutep Limited
+2.90% 271M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.42% 41.52B
LONZA GROUP AG Stock Lonza Group AG
+42.15% 39.9B
MODERNA, INC. Stock Moderna, Inc.
+1.97% 38.83B
CELLTRION, INC. Stock Celltrion, Inc.
-14.19% 26.05B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+1.82% 23.78B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.55% 18.26B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-4.07% 11.65B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+21.36% 11.53B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.20% 11.2B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IMM Stock